My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

49 50 Next >

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

March 20, 2025

Wrapping up Q4 earnings, we look at the numbers and key takeaways for the immuno-oncology stocks, including Natera (NASDAQ:NTRA) and its peers.

Via StockStory

Topics Artificial Intelligence

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

March 18, 2025

Via Benzinga

2 Large-Cap Stocks with Solid Fundamentals and 1 to Brush Off

March 17, 2025

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for...

Via StockStory

Friday's session: top gainers and losers in the S&P500 index ↗

March 14, 2025

Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

1 Dividend Stock Down 30% to Buy and Hold for the Next Decade ↗

March 09, 2025

Via The Motley Fool

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

February 21, 2025

Via Benzinga

This Company Just Initiated a Quarterly Dividend: Time to Buy? ↗

February 18, 2025

Via The Motley Fool

These S&P500 stocks are gapping in today's session ↗

March 14, 2025

Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends.

Via Chartmill

3 Stocks With Ironclad Balance Sheets for Long-Term Stability

March 13, 2025

Check out these three stocks with balance sheets that have a case for being among the strongest in the entire stock market.

Via MarketBeat

Topics Economy Supply Chain

What's going on in today's session: S&P500 gap up and gap down stocks ↗

March 12, 2025

Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.

Via Chartmill

Which S&P500 stocks are moving on Monday? ↗

March 10, 2025

Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session.

Via Chartmill

Looking Into Regeneron Pharmaceuticals's Recent Short Interest ↗

February 17, 2025

Via Benzinga

Top S&P500 movers in Monday's session ↗

March 10, 2025

Stay informed about the performance of the S&P500 index in the middle of the day on Monday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

Amgen And Kyowa Kirin's Rocatinlimab Reduces Eczema Severity In Phase 3 Study ↗

March 10, 2025

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints in IGNITE and SHUTTLE studies.

Via Benzinga

Eli Lilly's Single Monthly Maintenance Shot Of Eczema Drug Shows Completely Clear Skin At 3 Years In 50% Of Trial Patients ↗

March 07, 2025

Eli Lilly's Ebglyss showed sustained eczema relief, with 50% achieving full skin clearance and 87% maintaining near-clear skin over three years.

Via Benzinga

Biotech Rally Coming In Weeks Ahead? ↗

March 04, 2025

Large cap biopharma and MedTech stocks are leading the healthcare sector higher.

Via Talk Markets

Topics ETFs Stocks / Equities

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial ↗

March 03, 2025

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.

Via Benzinga

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

February 27, 2025

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

Via MarketBeat

Natera (NTRA) Q4 Earnings: What To Expect

February 26, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Regeneron Touts Encouraging Early Data From Investigational Gene Therapy For Rare Form Of Hearing Loss ↗

February 25, 2025

Regeneron's DB-OTO gene therapy shows improved hearing in 10 of 11 children in the CHORD trial, with three reaching near-normal levels at 24 weeks.

Via Benzinga

2 Healthcare Stocks with Big Upside and 1 to Skip

February 21, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...

Via StockStory

Topics Stocks

Eli Lilly Remains JPMorgan's Top Biopharma Pick For 2025, But Gilead And Bristol Myers Also Gain Praise — Is Retail On Board? ↗

February 21, 2025

JPMorgan sees Gilead well-positioned due to its strong HIV drug portfolio and disciplined expense management.

Via Stocktwits

Large Cap Biopharmaceutical Metrics And Performance Q1 2025 ↗

February 20, 2025

Tariffs could have big impact on earnings in 2025.

Via Talk Markets

Topics Stocks / Equities

Biogen Stock Is Mutating Into a Value Play

February 20, 2025

Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X

Via MarketBeat

Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect

February 18, 2025

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be announcing earnings results tomorrow after market close. Here’s what to look for.

Via StockStory

Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

February 14, 2025

Via Benzinga

Discover the top S&P500 movers in Wednesday's pre-market session. ↗

February 12, 2025

Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session.

Via Chartmill

How Databricks Pounced On AI Opportunity Amid Snowflake, Palantir Rivalries ↗

February 11, 2025

The rivalry between enterprise software makers Snowflake and Databricks intensified amid the emergence of generative artificial intelligence.

Via Investor's Business Daily

Topics Artificial Intelligence

Healthcare And Biotech Playbook As Disruption Gathers Force ↗

February 10, 2025

The XBI was down 1.54% for the week, like off a cliff on Friday from a Wednesday high of $94.82.

Via Talk Markets

Topics ETFs Stocks / Equities

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study ↗

February 10, 2025

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.